Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results (Q38582589)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 September 2015

Language	Label	Description	Also known as
English	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results	scientific article published on 07 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Angelo Delmonte

2

0 references

3

0 references

Daniele Calistri

4

0 references

author name string

Alice Pasini

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Emanuele Giordano

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

publication date

7 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1757-1771

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Management of non-small-cell lung cancer: recent developments

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Emerging new agents for the management of patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Genetic and epigenetic changes in lung carcinoma and their clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The significance of epigenetic alterations in lung carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The epigenomics of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Lung cancer: from single-gene methylation to methylome profiling.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Evolving concepts in lung carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Gene-promoter hypermethylation as a biomarker in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Epigenetic biomarkers in lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

DNA methylation markers and early recurrence in stage I lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Methylation of human microRNA genes in normal and neoplastic cells.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Genetic unmasking of an epigenetically silenced microRNA in human cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

CpG methylation is maintained in human cancer cells lacking DNMT1.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Epigenetic interplay between histone modifications and DNA methylation in gene silencing

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Global levels of histone modifications predict prognosis in different cancers

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Development of histone deacetylase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase 1 mRNA expression in lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone demethylation by a family of JmjC domain-containing proteins

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Regulation of chromatin by histone modifications

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone arginine methylation

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Cross-talk among epigenetic modifications: lessons from histone arginine methylation

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Readout of epigenetic modifications

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Cancer epigenetics reaches mainstream oncology

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Chromatin remodeling by polyamines and polyamine analogs

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Predicting response to epigenetic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

DNA methylation and gene silencing in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase inhibitors: a patent review (2009 - 2011).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Clinical and molecular responses in lung cancer patients receiving Romidepsin

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The future of epigenetic therapy in solid tumours--lessons from the past.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Polyamine-based small molecule epigenetic modulators.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

DNA methylation profiling in the clinic: applications and challenges

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0461-3

21 January 2018

Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between aberrant methylation and survival in non-small-cell lung cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery and development of DNA methylation-based biomarkers for lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/26347133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-015-0461-3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38582589&oldid=2201850790"